Theravance Biopharma, Inc. $TBPH Position Reduced by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP has reduced its stake in Theravance Biopharma, Inc. by 21.7%, selling 43,062 shares and now holding 155,429 shares worth approximately $1,388,000.
• Recent insider transaction includes SVP Rhonda Farnum selling 10,000 shares at an average price of $11.39, reducing her ownership to 326,918 shares valued at $3,723,596.
• Analysts have upgraded Theravance Biopharma to a consensus rating of "Strong Buy", with price targets reaching up to $25.00 from firms like BTIG Research.

Wellington Management Group LLP lessened its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 21.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 155,429 shares of the biopharmaceutical company's stock after selling 43,062 shares during the quarter. Wellington Management Group LLP owned 0.31% of Theravance Biopharma worth $1,388,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Aquatic Capital Management LLC acquired a new position in shares of Theravance Biopharma in the fourth quarter worth approximately $25,000. GAMMA Investing LLC lifted its holdings in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 3,281 shares in the last quarter. R Squared Ltd boosted its position in shares of Theravance Biopharma by 636.6% in the first quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock valued at $112,000 after acquiring an additional 10,822 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Theravance Biopharma by 142.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 12,670 shares of the biopharmaceutical company's stock valued at $119,000 after purchasing an additional 7,452 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in Theravance Biopharma during the 4th quarter valued at $119,000. 99.10% of the stock is owned by institutional investors.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president owned 326,918 shares of the company's stock, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

TBPH has been the topic of several research analyst reports. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a research report on Tuesday, June 17th. BTIG Research raised their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Finally, Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 15th. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Strong Buy" and a consensus target price of $21.33.

Theravance Biopharma Price Performance

Shares of TBPH traded up $0.20 during mid-day trading on Friday, hitting $14.25. The stock had a trading volume of 72,633 shares, compared to its average volume of 284,652. Theravance Biopharma, Inc. has a 52 week low of $7.88 and a 52 week high of $14.55. The business has a fifty day moving average price of $12.06 and a 200-day moving average price of $10.41. The firm has a market cap of $717.53 million, a P/E ratio of 59.20 and a beta of 0.05.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.